Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H.

Leukemia. 2019 Feb 6. doi: 10.1038/s41375-019-0395-y. [Epub ahead of print]

PMID:
30728457
2.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

3.

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Götze KS.

Oncotarget. 2018 Jun 12;9(45):27882-27894. doi: 10.18632/oncotarget.25328. eCollection 2018 Jun 12. Review.

4.

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.

Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A.

Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26.

PMID:
29396092
5.

A retrospective study evaluating the impact of infectious complications during azacitidine treatment.

Schuck A, Goette MC, Neukirchen J, Kuendgen A, Gattermann N, Schroeder T, Kobbe G, Germing U, Haas R.

Ann Hematol. 2017 Jul;96(7):1097-1104. doi: 10.1007/s00277-017-3001-2. Epub 2017 May 4.

PMID:
28474144
6.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. No abstract available.

7.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M.

Blood. 2016 Sep 8;128(10):1408-17. doi: 10.1182/blood-2016-05-714030. Epub 2016 Jul 6.

8.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

9.

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22.

PMID:
26341961
10.

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.

Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U.

Leuk Res. 2015 Jul;39(7):679-83. doi: 10.1016/j.leukres.2015.04.001. Epub 2015 Apr 15.

PMID:
25929166
11.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
12.

Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.

Lübbert M, Kuendgen A.

Cancer. 2015 Feb 15;121(4):498-501. doi: 10.1002/cncr.29083. Epub 2014 Oct 21. No abstract available.

13.

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Cancer. 2014 Jun 15;120(12):1838-46. doi: 10.1002/cncr.28663. Epub 2014 Apr 4.

14.

The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.

Kuendgen A.

Leuk Res. 2014 Mar;38(3):287-8. doi: 10.1016/j.leukres.2013.12.013. Epub 2013 Dec 26. No abstract available.

PMID:
24433864
15.

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K.

Blood. 2013 Jun 6;121(23):4769-77. doi: 10.1182/blood-2012-10-461624. Epub 2013 Apr 30.

16.

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G.

Blood. 2013 Apr 11;121(15):3005-15. doi: 10.1182/blood-2012-08-452938. Epub 2013 Jan 31.

17.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q).

Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.

18.

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub 2012 Oct 31.

PMID:
23122806
19.

Revised international prognostic scoring system for myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2012 Sep 20;120(12):2454-65. Epub 2012 Jun 27.

20.

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.

Kuendgen A, Bug G, Ottmann OG, Haase D, Schanz J, Hildebrandt B, Nachtkamp K, Neukirchen J, Dienst A, Haas R, Germing U, Gattermann N.

Clin Epigenetics. 2011 Aug;2(2):389-99. doi: 10.1007/s13148-011-0031-9. Epub 2011 Apr 8.

21.

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H.

Haematologica. 2012 Mar;97(3):393-401. doi: 10.3324/haematol.2011.048231. Epub 2011 Nov 4.

22.

Therapy-related myeloid neoplasms following treatment with radioiodine.

Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U.

Haematologica. 2012 Feb;97(2):206-12. doi: 10.3324/haematol.2011.049114. Epub 2011 Oct 11.

23.

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.

24.

An inexpensive way to treat elderly patients with high-risk MDS or AML.

Kuendgen A.

Leuk Res. 2011 Aug;35(8):985-6. doi: 10.1016/j.leukres.2011.03.026. Epub 2011 May 10. No abstract available.

PMID:
21561661
25.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.

26.

Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes.

Matsuda A, Germing U, Jinnai I, Araseki K, Kuendgen A, Strupp C, Iwanaga M, Miyazaki Y, Hata T, Bessho M, Gattermann N, Tomonaga M.

Leuk Res. 2010 Aug;34(8):974-80. doi: 10.1016/j.leukres.2009.11.015.

PMID:
20022110
27.

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.

Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U.

Eur J Haematol. 2009 Nov;83(5):477-82. doi: 10.1111/j.1600-0609.2009.01299.x. Epub 2009 Jun 22.

PMID:
19548919
28.

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.

Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U.

Leuk Res. 2009 Sep;33(9):1189-93. doi: 10.1016/j.leukres.2009.03.004. Epub 2009 May 9.

PMID:
19428106
29.

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, Haas R, Germing U.

Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.

30.

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.

Möller I, Blum S, Gattermann N, Haas R, Habersang K, Germing U, Kuendgen A.

Ann Hematol. 2009 Nov;88(11):1141-4. doi: 10.1007/s00277-009-0730-x. Epub 2009 Mar 17. No abstract available.

PMID:
19290525
31.

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AAN, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M.

Int J Hematol. 2009 Mar;89(2):173-187. doi: 10.1007/s12185-008-0242-9. Epub 2009 Jan 20.

PMID:
19152102
32.

Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.

Kuendgen A, Germing U.

Cancer Treat Rev. 2009 Apr;35(2):97-120. doi: 10.1016/j.ctrv.2008.09.001. Epub 2008 Oct 31. Review.

PMID:
18951721
33.

Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes.

Kuendgen A, Gattermann N, Germing U.

Leukemia. 2009 Jan;23(1):182-4; author reply 185. doi: 10.1038/leu.2008.153. Epub 2008 Jun 12. No abstract available.

PMID:
18548098
34.

Current status of epigenetic treatment in myelodysplastic syndromes.

Kuendgen A, Lübbert M.

Ann Hematol. 2008 Aug;87(8):601-11. doi: 10.1007/s00277-008-0477-9. Epub 2008 Apr 5. Review.

PMID:
18392623
35.

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M.

J Clin Oncol. 2007 Aug 10;25(23):3503-10.

PMID:
17687155
36.

Valproic acid for the treatment of myeloid malignancies.

Kuendgen A, Gattermann N.

Cancer. 2007 Sep 1;110(5):943-54. Review.

37.

Chronic myelomonocytic leukemia in the light of the WHO proposals.

Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N, Bennett JM.

Haematologica. 2007 Jul;92(7):974-7.

38.

Is lenalidomide a new standard treatment for myelodysplastic syndrome?

Kuendgen A.

Nat Clin Pract Oncol. 2007 Jul;4(7):396-7. Epub 2007 May 15. No abstract available.

PMID:
17502887
39.

Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.

Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, Strupp C, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Gattermann N, Aul C, Tomonaga M.

Leukemia. 2007 Apr;21(4):678-86. Epub 2007 Feb 1.

PMID:
17268513
40.

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.

Haematologica. 2006 Dec;91(12):1596-604.

41.

Myelodysplastic syndromes in patients younger than age 50.

Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U.

J Clin Oncol. 2006 Dec 1;24(34):5358-65. Epub 2006 Nov 6.

PMID:
17088566
42.

Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.

Kuendgen A, Gräf T, Zohren F, Hildebrandt B, Hünerlitürkoglu A, Gattermann N, Haas R, Kobbe G.

Leuk Res. 2007 Mar;31(3):407-9. Epub 2006 Aug 4.

PMID:
16890286
43.

Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.

Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R, Hünerlitürkoglu A, Haas R, Kobbe G.

Bone Marrow Transplant. 2006 Jul;38(1):69-70. Epub 2006 May 22. No abstract available.

PMID:
16715114
44.

Differences in epidemiology of MDS between Western and Eastern countries: Ethnic differences or environmental influence?

Kuendgen A, Matsuda A, Germing U.

Leuk Res. 2007 Jan;31(1):103-4. Epub 2006 Apr 19.

PMID:
16630658
45.

Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G.

Leuk Res. 2007 Feb;31(2):257-9. Epub 2006 Apr 18.

PMID:
16620971
46.

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

Germing U, Strupp C, Kuendgen A, Aivado M, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N.

Br J Haematol. 2006 Jan;132(2):162-7. Erratum in: Br J Haematol. 2006 Jul;134(2):247.

PMID:
16398650
47.

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.

Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N.

Cancer. 2006 Jan 1;106(1):112-9.

48.

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.

Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N.

Ann Hematol. 2005 Dec;84 Suppl 1:61-6.

PMID:
16270213
49.

Perspectives in the prognostication of myelodysplastic syndromes.

Germing U, Kuendgen A.

Haematologica. 2005 Sep;90(9):1157-9. No abstract available.

50.

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes.

Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M.

Blood. 2005 Oct 15;106(8):2633-40. Epub 2005 Jun 21.

Supplemental Content

Loading ...
Support Center